Skip to main content
SpringerLink
Log in

Drug combination therapy of systemic lupus erythematosus

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Conclusions

This long-term study on 73 patients with severe SLE has shown that drug combination therapy with steroids, CsA, MTX and Cy permits a control of disease activity and maintenance of kidney function with very few side effects and, to a large extent, allows patients a good quality of life in both professional and personal terms. In particular, it has been possible to drastically reduce steroid medication (Table 5). The mortality rate is now well under 1% per year, but is still three to four times higher than in an ageand sex-matched control population. Further efforts are necessary to improve the management of SLE. The investigation of the cytokine network might lead to the introduction of new agents [6]. There is also hope that CsA analogues, devoid of or with less toxicity, will be developed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beris P, Burger A, Favre L, Riondel A, Miescher PA (1986) Adrenocortical responsiveness after discontinuous corticosteroid therapy. Klin Wochenschr 64: 70

    Google Scholar 

  2. Esdaile JM (1994) Prognosis in systemic lupus erythematosus. Springer Semin Immunopathol 16: 337

    Google Scholar 

  3. Favre H (1973) Détermination des fonctions rénales par la technique de l'injection unique. Analyse statistique de modèle bicompartimental proposé par Sapirstein. J Urol Nephrol 79: 1007

    Google Scholar 

  4. Feutren G, Querin S, Tron F, Noel LH, Chatenoud L, Lesavre P, Bach JF (1986) The effects of cyclosporine in patients with systemic lupus. Transplant Proc 18: 643 factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027

    Google Scholar 

  5. Horwitz DA, Jacob CO (1994) The role of cytokines in the pathogenesis of systemic lupus erythematosus. Springer Semin Immunopathol 16: 181

    Google Scholar 

  6. Huang YP, Miescher PA, Zubler RH (1986) The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 137: 3515

    Google Scholar 

  7. Huang YP, Perrin LH, Miescher PA, Zubler RH (1988) Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 141: 827

    Google Scholar 

  8. Huang YP, Pechere JC, Michel M, Gauthey L, Loreto M, Curran JA, Michel JP (1992) In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women. J Immunol 148: 715

    Google Scholar 

  9. Izui S, Lambert PH, Miescher PA (1976) Dtermination of anti-DNA antibodiesby a modified 1251-labelled DNA-binding test. Estimation of non-specific binding of DNA to non-immunoglobulin basic proteins by using an anitonic detergent. Clin Exp Immunol 26: 423

    Google Scholar 

  10. McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E (1991) Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 34: 1268

    Google Scholar 

  11. Miescher PA, Favre H, Chatelanat F, Mihatsch MJ (1987) Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Klin Wochenschr 65: 727

    Google Scholar 

  12. Miescher PA, Huang YP, Zubler RH (1988) New approaches to the treatment of RA. Springer Semin. Immunopathol 10: 251

    Google Scholar 

  13. Perrin LH, Lambert PH, Nydegger U, Miescher PA (1973) Quantitation of C3PA and other complement components in diseases associated with a low C3 level. Clin Immunol Immunopathol 2: 16

    Google Scholar 

  14. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172

    CAS  PubMed  Google Scholar 

  15. Steinberg AD, Steinberg S (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945

    Google Scholar 

  16. Waldmann TA (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14: 264

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, Geneva University Hospital, CH-1211, Geneva 4, Switzerland

    Peter A. Miescher & You-Peng Huang

  2. Division of Nephrology, Geneva University Hospital, CH-1211, Geneva 4, Switzerland

    Hervé Favre

  3. Institute of Clinical Pathology, Geneva University Hospital, CH-1211, Geneva 4, Switzerland

    Robert Lemoine

Authors
  1. Peter A. Miescher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hervé Favre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Lemoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. You-Peng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miescher, P.A., Favre, H., Lemoine, R. et al. Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 16, 295–311 (1994). https://doi.org/10.1007/BF00197523

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00197523

Keywords

Search

Navigation